STOCK TITAN

Sanofi FR Stock Price, News & Analysis

SNY Nasdaq

Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.

Sanofi (SNY), a global leader in pharmaceuticals and vaccines, provides critical health solutions through its innovative drug development and strategic partnerships. This dedicated news hub offers investors and industry professionals centralized access to official updates and analysis.

Track SNY's latest press releases covering clinical trial results, regulatory approvals, and financial earnings. Our curated collection simplifies monitoring of key developments in oncology, immunology treatments, and vaccine innovations that shape global healthcare markets.

Discover timely updates on Sanofi's strategic collaborations, manufacturing expansions, and R&D breakthroughs. The resource serves both casual observers and professional analysts seeking unfiltered information about this Paris-based healthcare giant's market activities.

Bookmark this page for streamlined access to SNY's evolving story in the pharmaceutical sector. Verify facts directly from source materials while staying informed about developments impacting one of Europe's most significant healthcare enterprises.

Rhea-AI Summary

Regeneron and Sanofi announced positive results from the Phase 3 PRIME2 trial for Dupixent (dupilumab), showing significant effectiveness in treating prurigo nodularis. At 12 weeks, 37% of patients on Dupixent experienced meaningful itch reduction, compared to 22% on placebo. By 24 weeks, this increased to 58% vs 20%. Dupixent also improved skin clarity in 45% of patients. Regulatory filings for Dupixent's approval in prurigo nodularis are planned for 2022. Safety results were consistent with its existing profile, although some adverse events were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Seagen and Sanofi have entered an exclusive collaboration to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. This partnership combines Sanofi's monoclonal antibody technology with Seagen's ADC technology. Both companies will co-fund global development activities and share future profits. Sanofi will also provide undisclosed payments for the selected targets. The first target has already been designated, aligning with Seagen's strategy to advance cancer treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary

Regeneron and Sanofi announced positive Phase 3 trial results for Dupixent (dupilumab) 300 mg weekly in treating eosinophilic esophagitis (EoE), a chronic inflammatory disease. The trial showed a 64% reduction in disease symptoms after 24 weeks compared to placebo, with 59% of Dupixent patients achieving histological remission. The safety profile was consistent with previous studies. Regulatory filings are expected in 2022. EoE affects around 160,000 patients in the U.S., highlighting the potential market for Dupixent in this indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary

Sanofi announced a collaboration with Breast International Group (BIG), EORTC, and AFT to initiate the Phase 3 AMEERA-6 study, focusing on the oral selective estrogen receptor degrader (SERD) amcenestrant for estrogen receptor-positive breast cancer in patients unable to continue aromatase inhibitor therapy. The trial aims to evaluate amcenestrant's efficacy and safety against tamoxifen. Sanofi will sponsor the study, which is crucial for providing alternatives in adjuvant therapy to combat disease recurrence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

Sanofi and Merck have announced that Vaxelis, the first hexavalent combination vaccine in the U.S., is now available. This vaccine protects against six diseases: diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B, administered in three doses to children aged 6 weeks to 4 years. The vaccine aims to reduce the number of shots children need, improving vaccination coverage. Vaxelis has been included in the CDC's immunization schedule and will be distributed through various channels. The collaboration reflects a commitment to enhancing pediatric health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
Rhea-AI Summary

Sanofi has announced a three-year research collaboration with Stanford University School of Medicine, aiming to deepen the understanding of immunology and inflammation. The partnership will explore autoimmune diseases and inflammatory conditions, with funding for up to three joint programs annually. Initial projects will focus on type 2 inflammation, T cell mechanisms in autoimmunity, and immune-related adverse events. This collaboration strengthens Sanofi's commitment to research and innovation within immunoscience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary

Sanofi has partnered with Moderna to manufacture up to 200 million doses of its COVID-19 vaccine, utilizing its Ridgefield, NJ facility starting September 2021. This represents Sanofi's third manufacturing commitment in response to the pandemic, having previously supported BioNTech and Johnson & Johnson. The company is also developing its COVID-19 vaccine candidates in collaboration with GSK and Translate Bio. Sanofi aims to enhance global vaccine supply while continuing its internal vaccine development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
covid-19
-
Rhea-AI Summary

On April 7, 2021, Sanofi announced the creation of Sanofi Global Health, a new nonprofit unit aimed at enhancing access to essential medicines in 40 lower-income countries. The initiative will provide 30 medicines across various therapeutic areas, alongside support for healthcare professionals. Additionally, Sanofi plans to donate 100,000 vials of treatments annually for rare diseases. The company also committed to reducing greenhouse gas emissions by 55% by 2030 and implementing zero plastic packaging for vaccines by 2027, while promoting diversity within its workforce.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
Rhea-AI Summary

The FDA has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) after one to three prior treatments. The approval is based on the Phase 3 IKEMA study, which demonstrated a 45% reduction in disease progression or death risk. Sarclisa now has two FDA-approved combinations for RRMM. Despite challenges in treating relapsed MM, the approval positions Sarclisa as a potential standard of care, enhancing its market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags

FAQ

What is the current stock price of Sanofi FR (SNY)?

The current stock price of Sanofi FR (SNY) is $48.3 as of July 3, 2025.

What is the market cap of Sanofi FR (SNY)?

The market cap of Sanofi FR (SNY) is approximately 117.8B.
Sanofi FR

Nasdaq:SNY

SNY Rankings

SNY Stock Data

117.78B
2.53B
0%
10.61%
0.22%
Drug Manufacturers - General
Healthcare
Link
France
Paris